The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.

The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.

Disclosed herein are materials and methods for the treatment of stress-related disorders and cancer.

Disclosed herein are materials and methods for the treatment of stress-related disorders and cancer.

A kit and sterile preparation of purified corticotropin and methods relating thereto in which the preparation includes corticotropin extracted from a whole porcine pituitary gland including both anterior and posterior portions, and having proteins or peptides having a molecular weight higher than 4.6 kDa removed. Methods of manufacturing, testing, increasing stability, storage, and use of the purified corticotropin are also provided.

A kit and sterile preparation of purified corticotropin and methods relating thereto in which the preparation includes corticotropin extracted from a whole porcine pituitary gland including both anterior and posterior portions, and having proteins or peptides having a molecular weight higher than 4.6 kDa removed. Methods of manufacturing, testing, increasing stability, storage, and use of the purified corticotropin are also provided.

The disclosure provides a simple and rapid blood-based bioassay useful in the diagnosis, treatment and monitoring of eosinophilic gastrointestinal disorders, and related compositions and methods.

Provided herein are methods of administering a repository corticotropin pharmaceutical composition in a pre-filled manual apparatus for an adult patient 18 years old or a pediatric patient 2 years of age by an adult of at least 18 years of age to deliver a one-time use dose only. The manual injector apparatus is capable of being stored at room temperature for up to 24 hours prior to administration and the repository corticotropin pharmaceutical composition is a naturally sourced complex mixture comprising N-25 deamidated porcine ACTH (1-39).

Provided herein are methods of administering a repository corticotropin pharmaceutical composition in a pre-filled manual apparatus for an adult patient 18 years old or a pediatric patient 2 years of age by an adult of at least 18 years of age to deliver a one-time use dose only. The manual injector apparatus is capable of being stored at room temperature for up to 24 hours prior to administration and the repository corticotropin pharmaceutical composition is a naturally sourced complex mixture comprising N-25 deamidated porcine ACTH (1-39).

Polypeptide preparation methods of preparing high-purity ACTH (human sequence) or analogue and large-scale preparation method thereof are described. The main steps include: amino acids are coupled from the C-terminal to the N-terminal by Fmoc solid-phase synthesis method to obtain the crude ACTH (human sequence) or analogue peptidyl-resin with protective groups, wherein the reaction temperature of C-15 peptide synthesis is 40-60 C. After cleavage and precipitation, the crude product of ACTH (human sequence) or analogue is obtained, and then the high-purity product is obtained by liquid chromatography. The chromatographic purity of ACTH (human sequence) or analogue prepared by the invention is more than 99%, the stability is good, and the yield of the target peptide is 63%.